With a $14 million research grant, Cystic Fibrosis Foundation Therapeutics will expand its research partnership with Genzyme to develop therapy options for cystic fibrosis patients with the common mutation F508del.

The funding from CFF Therapeutics will be used specifically in Genzyme’s R&D programs and was granted in order to support studies to identify new compounds able to repair the defective CFTR protein present in CF patients. The research is focused on the F508del mutation since about 90% of the 30,000 people who live with the disease in the U.S. have at least one copy of it.

“The Foundation is focused on supporting the discovery and development of powerful new therapies that attack the underlying cause of this deadly disease,” stated the president and CEO of the CFF, Robert J. Beall, PhD in a press release. “We are pleased to continue CFFT’s agreement with Genzyme and are excited by the possibilities of what our pooled knowledge, expertise and resources can bring.”

View the full story at www.cysticfibrosisnewstoday.com